BioAtla BCAB
OTC BCAB
$1.80 -0.01 (-0.55%)
At close: Nov 10, 2026 · 4:00 PM EST

BioAtla (BCAB) EBT Margin (2020 - 2026)

Updated

BioAtla's EBT Margin was 3.74% in Q2 2026.

Analysis

BioAtla (BCAB) EBT Margin (2020 - 2026) Analysis & Trends

On a trailing twelve-month basis, BioAtla's EBT Margin was -374.89% through Jun 30, 2026, up 145.24 percentage points year-over-year; for FY2025, it was -2923.10%, down 2281.52 percentage points from FY2024.

  • EBT Margin shows a five-year change of +4393.45 percentage points (FY2020 to FY2025).
  • In earlier years, EBT Margin was -641.58% in FY2024 and -38437.20% in FY2021 (-31120.65 pp).
  • The Q2 2026 figure marks the highest quarterly EBT Margin in data going back to Q1 2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 0.13%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 27.75%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 30.74%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 26.27%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 45.21%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 36.90%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 20.41%
10 BioAtla 2.99 Mn -15.95 Mn - 3.74%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 3.74%
Dec 31, 2025 -459.10%
Sep 30, 2024 -96.16%
Jun 30, 2024 -2,341.33%
Jun 30, 2021 -12,152.40%
Sep 30, 2020 -5,380.00%
Jun 30, 2020 -2,775.26%
Mar 31, 2020 -1,855.06%
API Access

BioAtla EBT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebt-margin&ticker=BCAB&period=max&api_key=YOUR_API_KEY